Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Interest Income

Income earned on cash, deposits, and investments held by the company.

Upstream Bio, Inc.NASDAQ: UPB

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $3.05M fell 35.6% year over year, behind the -2.3% change in trailing-twelve-month interest income. Sequentially, it fell 16.4% from the prior quarter. Over 3 fiscal years it compounded at +335.5% a year.

Context

  • Interest income amounted to 593.3% of revenue in FY2025, up 81.8 pp from a year earlier.
  • Interest income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -35.6% toward the trailing-twelve-month pace of -2.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.05M-16.4% QoQ
Last fiscal yearDec 2025
$16.93M+39.7% YoY
LTMMar 2026
$15.24M-2.3% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.6%——
1 year+39.7%——
3-year CAGR+335.5%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
16.93M USD
Year-over-year change
+39.7%
3-year CAGR
+335.5%

Interest Income vs competitors

How UPB compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2.3% is the 5th highest of 8, against a peer median of +0.7%.
  • Interest income amounts to 458.9% of revenue for UPB, versus a peer median of 28.2%.
UPB Competitors
Interest Income for UPB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$34.81M USD+48.0%+209.8%38.5%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$25.8M USD-41.1%+50.6%39.0%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$24.58M USD-23.6%+45.4%237.5%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$24.38M USD-6.3%+57.0%11.2%
UPBUpstream Bio, Inc.LTM Mar 2026$15.24M USD-2.3%+335.5%458.9%
WVEWave Life Sciences Ltd.LTM Mar 2026$12.89M USD+22.8%—18.0%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$12.37M USD+48.5%+29.4%—
PHVSPharvaris N.V.LTM Sep 2026€5.68M EUR+0.7%——
ZBIOZenas BioPharma, Inc.LTM Mar 2026$3.02M USD———
NVAXNovavax, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding UPB) —+0.7%+50.6%28.2%

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.21M2.38M2.37M2.85M
Cost of Revenue0000
Gross Profit1.21M2.38M2.37M2.85M
Gross Margin100.0%100.0%100.0%100.0%
Research & Development18.66M31.8M62.97M136.81M
Selling, General & Admin6.46M10.7M17.17M26.41M
Operating Expenses25.12M42.49M80.13M163.22M
Depreciation & Amortization7K60K89K188K
EBITDA(23.86M)(20.48M)(62.72M)(143.26M)
EBITDA Margin-1968.7%-860.4%-2646.3%-5019.4%
Operating Income(23.91M)(40.11M)(77.76M)(160.36M)
Operating Margin-1972.7%-1685.5%-3281.2%-5618.8%
Interest Income205K4.17M12.12M16.93M
Interest Expense0000
Other Income / Expenses41K19.58M14.96M16.92M
Income Before Tax(23.87M)(20.54M)(62.81M)(143.44M)
Pre-Tax Margin-1969.3%-862.9%-2650.0%-5026.0%
Income Tax Expense0000
Net Income(23.87M)(20.54M)(62.81M)(143.44M)
Net Margin-1969.3%-862.9%-2650.0%-5026.0%
EPS (Basic)(0.66)(1.05)(1.49)(2.66)
EPS (Diluted)(0.66)(1.05)(1.49)(2.66)
Weighted Avg Shares36.32M36.32M51.34M53.85M
Weighted Avg Shares (Diluted)36.32M36.32M51.34M53.85M

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.